Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
ID06999902

A Double-Blind, Randomized, Multicenter Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)

Led by Praxis Precision Medicines · Updated on 2025-05-31

230

Participants Needed

26

Research Sites

2 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research investigates PRAX-628, a medication being studied for adults with focal seizures who are currently taking between one and three anti-seizure medications. The trial is designed as a double-blind, randomized, multicenter study to assess the medication's safety and how well it works in reducing seizure frequency. The study is sponsored by Praxis Precision Medicines and focuses on adults aged 18 to 75 with a confirmed diagnosis of focal onset epilepsy. Participants are randomly assigned to one of two groups. One group receives PRAX-628 orally once daily, starting with 20 mg for the first six weeks, then increasing to 30 mg for the next six weeks. The other group receives a matching placebo once daily for the entire 12-week treatment period. The study is carefully controlled to keep participants and researchers unaware of the assigned treatment to accurately evaluate outcomes. During the 12-week treatment period, participants will be monitored regularly to assess seizure frequency, safety, and tolerability of the medication. Researchers will use imaging tests like CT or MRI to confirm eligibility before enrollment and exclude participants with certain medical histories. The primary measure is the change in focal seizure frequency over the 12 weeks. The study includes safety checks, and all participants' health will be closely observed throughout the trial until its completion in December 2025.

CONDITIONS

Brief Title

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • Diagnosed with focal onset epilepsy according to the International League Against Epilepsy (ILAE) Classification
  • Past CT or MRI imaging showing no progressive cause of epilepsy
  • Currently taking at least 1 and no more than 3 acceptable anti-seizure medications
Not Eligible

You will not qualify if you...

  • History within 12 months of pseudo or psychogenic seizures, uncountable cluster seizures, convulsive status epilepticus requiring hospitalization and intubation, or only focal seizures with awareness without motor activity
  • Planned epilepsy surgery during the trial
  • Neurosurgery for seizures less than 1 year before enrollment, radiosurgery less than 2 years before enrollment, or vagus nerve stimulation implantation
  • History of schizophrenia, obsessive-compulsive disorder, or other serious mental health disorders
  • History of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years
  • History of cardiac disease, cardiac conduction disorders, or cardiac structural abnormalities
  • Positive test or known history of HIV, hepatitis B surface antigen, or hepatitis C virus antibody at screening
  • Pregnant, breastfeeding, positive pregnancy test at screening, or planning pregnancy during the trial or within 14 days after last study drug dose
  • Use of any other experimental drug, device, or gene therapy within 30 days or 5 half-lives prior to screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 12 weeks

Participants take either PRAX-628 or placebo once daily. The dose of PRAX-628 starts at 20 mg per day for 6 weeks, then increases to 30 mg per day for the remaining 6 weeks.

Visits as required for dosing and safety monitoring

Trial Site Locations

Total: 26 locations

1

Praxis Research Site

Phoenix, Arizona, United States, 85032

Actively Recruiting

2

Praxis Research Site

DeLand, Florida, United States, 32720

Actively Recruiting

3

Praxis Research Site

Miami Lakes, Florida, United States, 33016

Actively Recruiting

4

Praxis Research Site

Chicago, Illinois, United States, 60640

Actively Recruiting

5

Praxis Research Site

Lafayette, Louisiana, United States, 70508

Actively Recruiting

6

Praxis Research Site

Bethesda, Maryland, United States, 20817

Actively Recruiting

7

Praxis Research Site

Chesterfield, Missouri, United States, 63005

Actively Recruiting

8

Praxis Research Site

Ozark, Missouri, United States, 65721

Actively Recruiting

9

Praxis Research Site

Hackensack, New Jersey, United States, 07601

Actively Recruiting

10

Praxis Research Site

Middletown, New York, United States, 10940

Actively Recruiting

11

Praxis Research Site

Canton, Ohio, United States, 44718

Actively Recruiting

12

Praxis Research Site

Oklahoma City, Oklahoma, United States, 73112

Actively Recruiting

13

Praxis Research Site

El Paso, Texas, United States, 79912

Actively Recruiting

14

Praxis Research Site

Frisco, Texas, United States, 75034

Actively Recruiting

15

Praxis Research Site

Round Rock, Texas, United States, 78681

Actively Recruiting

16

Praxis Research Site

Seabrook, Texas, United States, 77586

Actively Recruiting

17

Praxis Research Site

Barcelona, Spain, 08003

Actively Recruiting

18

Praxis Research Site

Barcelona, Spain, 08035

Actively Recruiting

19

Praxis Research Site

Barcelona, Spain, 08041

Actively Recruiting

20

Praxis Research Site

Granda, Spain, 18012

Actively Recruiting

21

Praxis Research Site

Madrid, Spain, 28006

Actively Recruiting

22

Praxis Research Site

Madrid, Spain, 28010

Actively Recruiting

23

Praxis Research Site

Madrid, Spain, 28040

Actively Recruiting

24

Praxis Research Site

Málaga, Spain, 29010

Actively Recruiting

25

Praxis Research Site

Terrassa, Spain, 08222

Actively Recruiting

26

Praxis Research Site

Valencia, Spain, 46026

Actively Recruiting

Loading map...

Research Team

H

Head of Pharmacovigilance

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

An Open-label, Long-term Study Evaluating RAP-219 in Adult P...

Focal Epilepsy

Actively Recruiting

7 locations

A Phase 3, Randomized, Double-blind, Placebo-controlled Stud...

Focal Seizure

Actively Recruiting

2 locations

A Phase 3 Randomized Study of RAP-219 to Evaluate Safety and...

Focal Seizure

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here